Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:08:44.497Z.
Calculation as of: 2026-10-06T19:08:44.497Z.
Quote observation: 2026-10-06T19:01:35.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f0d9278b3abed9c67286a4c42ed3cbe71797fc66aa4bad88dc285e5ed2b1466
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$68.47M
EV/EBIT Ratio
N/A
TTM Avg
25.28x
3Y Avg
28.49x
5Y Avg
157.43x
Market Cap
$63.16M
EV/EBIT Ratio
N/A
TTM Avg
31.50x
3Y Avg
31.50x
5Y Avg
31.50x
Market Cap
$68.90M
EV/EBIT Ratio
3.35x
TTM Avg
7.89x
3Y Avg
4.27x
5Y Avg
4.27x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XBiotech Inc. (XBIT) | $66.01M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $66.56M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $66.94M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $64.97M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $63.56M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $68.47M | N/A | 25.28x | 28.49x | 157.43x |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | N/A | 31.50x | 31.50x | 31.50x |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 3.35x | 7.89x | 4.27x | 4.27x |
| InterCure Ltd. (INCR)vs › | $63.02M | N/A | 9.73x | 23.03x | 21.55x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
